PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.
0.07
OCF/share of 0.07 while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss would see if modest cash generation can build a stronger lead.
0.05
FCF/share of 0.05 while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss would see if small leftover cash can become a big advantage.
28.46%
Capex/OCF ratio of 28.46% while the Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss would confirm if minimal reinvestment is enough for advantage.
-0.36
Negative ratio while Drug Manufacturers - Specialty & Generic median is 0.28. Seth Klarman might see a severe mismatch of earnings and cash.
23.67%
OCF-to-sales ratio of 23.67% while Drug Manufacturers - Specialty & Generic is zero. Walter Schloss might see a modest advantage in actually generating some cash.